Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
about
Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsA consensus statement on the gender perspective in lung cancer.Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibImmune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung CancerAfatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on AfatinibDistribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer.Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer.Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations.Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.Score for lung adenocarcinoma in China with EGFR mutation of exon 19: Combination of clinical and radiological characteristics analysis
P2860
Q28075291-91B39C2E-AB82-4FAA-AF85-89D95BE240E3Q30240700-3BA7464A-7948-4822-A8B1-5DD7DEE3AC7AQ33621143-AE662139-23A0-4CA3-80EB-D35F7F28D589Q34497467-413068A4-7AD6-436A-93A1-86AE705289ABQ35807946-5C36AB56-D817-4EDF-BCBC-12B009DC98CDQ36088496-1FAD3197-6DE3-4C16-9430-F6BDABA5A65AQ36092880-EE9FEB3D-4ACC-41EA-A924-928B3823E192Q39339545-E317F64F-0180-4F7F-9EB2-9826E2B5156FQ39711633-BBE8A5B7-B730-469F-92EE-0CF579CDBB58Q40498036-28D3DF5C-20FE-41DE-A3DF-03E020484161Q47155769-1D58E453-B250-4352-9636-9F4FAD43A44EQ47715187-DE5CB5F6-032A-455E-86B9-17A46A97F3EFQ49300205-C2F5DF98-2F0F-41F0-B794-0915D04FDFCDQ52318443-DDD5E9BB-6ABA-4D50-9BB7-676DAB454D64Q54981628-FBF51DA1-A271-46D7-A1EB-75B9114F4EC1Q55181387-967F6022-5AF2-4DDF-ACAF-B0564D8D2CB0Q55224621-1D3ADFFC-095D-491C-ACAA-B2DC3817EE0CQ58704176-4B864102-2613-44D0-95DC-6825A49FE875
P2860
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Common EGFR-mutated subgroups ...... th tyrosine kinase inhibitors.
@en
type
label
Common EGFR-mutated subgroups ...... th tyrosine kinase inhibitors.
@en
prefLabel
Common EGFR-mutated subgroups ...... th tyrosine kinase inhibitors.
@en
P2860
P356
P1433
P1476
Common EGFR-mutated subgroups ...... th tyrosine kinase inhibitors.
@en
P2093
Jordi Remon
Noemi Reguart
P2860
P304
P356
10.2217/FON.15.15
P407
P577
2015-01-28T00:00:00Z